For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
2d
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price ...
Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...
Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu ...
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...
Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) ...
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...
Also, Nintendo Switch 2 launches into a changed market where players have come to expect that they will be able to carry their game libraries forward from one machine to another, which precluded a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback